N@N

BioSyntech announces second quarter fiscal 2010 financial results

^{Published on 2009-11-13 11:02:38 - Market Wire}
 

 - Appointed Ms. Jeanne M. Bertonis to the position of Chief Executive Officer and Ms. Antoinette Lizzi to the position of Chief Financial Officer. - Raised $1.4 million in a non-brokered private placement consisting of 140,000 units of BioSyntech, each comprised of $10 principal amount of subordinated secured convertible debentures and 91 common share purchase warrants at a price of $10 per Unit. - Subsequent to quarter-end, closed rights offering for gross aggregate proceeds of $3.1 million. - Interim analysis of clinical data from 41 patients in the ongoing Canadian/European clinical trial is being finalized, including MRI data.